Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Cognitive Behavioral Therapy for Depression
NCT05227612Phase 1Completed
- Sponsor
- University of California, Los Angeles
- Start
- Jun 2023
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by University of California, Los Angeles. Primary endpoints: Client Satisfaction Questionnaire-8 at 4 months, Study Feasibility at 4 months and 2 more. Started Jun 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05227612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227612.